- Open Access
The multiple functions of the endocannabinoid system: a focus on the regulation of food intake
Diabetology & Metabolic Syndrome volume 2, Article number: 5 (2010)
Cannabis sativa (also known as marijuana) has been cultivated by man for more than 5,000 years. However, there was a rise in its use in the 20th century for recreational, religious or spiritual, and medicinal purposes. The main psychoactive constituent of cannabis, whose structure was identified in the 1960's, is Δ9-tetrahydrocannabinol. On the other hand, the discovery of cannabinoid receptors and their endogenous agonists took place only very recently. In fact, the first cannabinoid receptor (CB1) was cloned in 1990, followed 3 years later by the characterization of a second cannabinoid receptor (CB2). Since the 19th century, the use of cannabis has been reported to stimulate appetite and increase the consumption of sweet and tasty food, sometimes resulting in significant weight gain. The recent description of the endocannabinoid system, not only in the central nervous system but also in peripheral tissues, points to its involvement in the regulation of appetite, food intake and energy metabolism. Consequently, the pharmacological modulation of the over-activity of this system could be useful in the treatment of the metabolic syndrome.
The endocannabinoid system has important physiological functions not only in the central nervous system but also in peripheral tissues. The activation of central CB1 receptors, particularly in hypothalamic nuclei and in the limbic system, is involved in the regulation of feeding behavior, and especially in the control of the intake of palatable food. In the periphery, cannabinoid receptors are present in adipocytes, skeletal muscle, gastrointestinal tract and liver, modulating energy metabolism.
Cannabis sativa (marijuana or cannabis) has been cultivated by man since approximately 4,000 B.C [1, 2]. At that time, the fibers obtained from the cannabis stems were mainly used to manufacture textiles and paper . Moreover, from that time on, cannabis has also been known to have a variety of medicinal effects unrelated to its psychoactive properties, including effects on anorexia, emesis, pain, inflammation and neurodegenerative disorders . Cannabis is the most widely used illicit drug in Western societies and also the one with the longest recorded history of human use. The popularity of marijuana as a recreational drug is due to its ability to alter sensory perception and cause elation and euphoria .
It has also been known since 300 B.C. that the recreational use of cannabis stimulates appetite, especially for sweet and palatable food [4, 5]. Nevertheless, this phenomenon was seriously taken into consideration in biomedical research only in the last decade, after the description of the existence of an endogenous cannabinoid system [6, 7], providing a physiological basis for the biological effects induced by cannabis and its derivatives.
Several chemical constituents of cannabis have already been identified, but its main psychoactive constituent is considered to be Δ9-tetrahydrocannabinol (Δ9-THC), whose structure was identified in the 1960's . Even though several naturally-occurring agonists of the endogenous cannabinoid system have been known since then, the discovery of cannabinoid receptors and their endogenous agonists took place only very recently. In fact, the first cannabinoid receptor (CB1) was cloned in 1990 , followed 3 years later by the characterization of a second cannabinoid receptor (CB2) .
The endocannabinoid system
Cannabinoid receptors belong to the G protein-coupled receptor superfamily and their activation modulates adenylate-cyclase, potassium and calcium channels and transcription factors such as mitogen-activated protein kinase [6, 11]. The CB1 cannabinoid receptor is widely expressed in the central nervous system as well as in the periphery, while CB2 is mainly expressed in immune cells. In the central nervous system, CB1 is predominantly expressed presynaptically, modulating the release of neurotransmitters, including γ-aminobutyric acid (GABA), dopamine, noradrenaline, glutamate and serotonin .
The discovery of specific receptors mediating the actions of cannabis led to the search for endogenous ligands for cannabinoid receptors. The first endogenous cannabinoid, arachidonoyl ethanolamide, was identified in 1992 and was named anandamide, from the Sanskrit word 'ananda', meaning internal ecstasy [13, 14]. Thus, both plant-derived (Δ9-THC) and endogenous (anandamide) agonists bind to the same cannabinoid receptors (Figure 1). Since the discovery of anandamide, other polyunsaturated fatty acid derivatives acting as functional agonists of cannabinoid receptors have been characterized and collectively termed endocannabinoids . In contrast to classical neurotransmitters such as the catecholamines, endocannabinoids are not stored in the interior of synaptic vesicles because of the high lipophilicity of these ligands . These findings led to the conclusion that the endocannabinoid system acts "on demand", meaning that the endocannabinoids are synthesized and released upon physiological or pathological stimulation .
The endocannabinoid system and the regulation of food intake and energy metabolism
Since the 19th century the use of cannabis has been reported to stimulate appetite and to increase the consumption of sweet and tasty food, sometimes resulting in significant weight gain [4, 16]. The recent description of the endocannabinoid system, not only in the central nervous system but also in peripheral tissues, points to its involvement in the regulation of appetite, food intake and energy metabolism [17–20]. Numerous experimental data have confirmed this hypothesis and will be briefly summarized below, while clinical results will be presented in the next topic of this article.
Endocannabinoid actions in the central nervous system
It has already been demonstrated that endocannabinoids initiate appetite by stimulation of CB1 receptors in hypothalamic areas involved in the control of food intake, such as the ventromedial hypothalamus (VMH)  (Figure 2). For instance, the injection of anandamide in the VMH of pre-satiated rats induces hyperphagia, which is prevented by previous hypothalamic administration of the selective CB1 cannabinoid antagonist rimonabant . Using another experimental approach, Kirkham et al.  evaluated endocannabinoid levels in relation to the feeding behavior of rats in the hypothalamus and in the limbic forebrain, including the shell area of the nucleus accumbens, which is known to be linked to eating motivation. Endocannabinoid levels increased during fasting and declined during feeding, while no changes were detected in satiated rats. On the other hand, endocannabinoid levels in the cerebellum, which is not directly involved in the control of food intake, were unaffected by feeding behavior. Moreover, the injection of endocannabinoids into the nucleus accumbens induced feeding behavior, an effect that was also attenuated by rimonabant .
The experimental model of CB1 receptor knockout (CB1-/-) mice has also been used to clarify the involvement of the endocannabinoid system in the regulation of energy metabolism. An elegant study conducted by Ravinet-Trillou et al. compared CB1-/- knockout male mice with wild-type animals (CB1+/+) exposed either to a standard laboratory regimen or to a high-fat diet (HFD) . When maintained on the standard diet, CB1-/- mice are lean and their body weight and adiposity are, respectively, 24 and 60% lower than that of CB1+/+ mice. CB1-/- mice submitted to the HFD do not develop obesity and do not display hyperphagia in contrast to CB1+/+ mice, and their feeding efficiency remains low. Furthermore, the insulin resistance that occurs in HFD-fed mice is not present in CB1-/- mice. These results led to the conclusion that CB1 receptors are involved not only in the development of diet-induced obesity but also in peripheral metabolic regulations . These results were confirmed by Cota et al. , who showed that CB1-/- mice exhibit reduced spontaneous caloric intake and total fat mass, decreased body weight, and hypophagia, when compared with CB1+/+ littermates. Moreover, in young CB1-/- mice, the lean phenotype is predominantly caused by decreased caloric intake, whereas in adult CB1-/- mice, metabolic factors appear to contribute to the lean phenotype .
Another study carried out in mice submitted to HFD showed that a short-lasting reduction of food intake induced by a chronic oral treatment with rimonabant is dissociated from the long-lasting reduction of body weight and obesity. Moreover, rimonabant reverses the insulin resistance and lowered plasma leptin, insulin, and free fatty acid levels in this model of diet-induced obesity .
It is also noteworthy that Δ9-THC increases not only total food intake but also specifically increases the consumption of sweets, suggesting an interaction between the effect of the drug and the palatability of the food . Another investigation confirmed this notion showing that different routes of Δ9-THC administration (oral, smoke inhalation or suppository) induced an effect on food selection . Moreover, this selective action on food choice was confirmed in a number of animal studies, in which a potential role of cannabinoids in modulating the interaction of different pathways involved in the brain 'reward' system was hypothesized [29, 30]. Thus, endocannabinoid signaling is involved orexigenically in both the homeostatic and the hedonistic control of food intake .
Endocannabinoid actions in the periphery
A functional CB1 receptor has already been identified in the fat tissue of rodents . The CB1 receptor is expressed both in epididymal fat pads extracted from mice and in primary adipocyte cell cultures and seems to be involved in the regulation of lipogenesis. Moreover, the receptor is expressed in fat tissue obtained from CB1+/+, but not CB1-/- knockout, mice. CB1 agonists dose-dependently increase lipoprotein lipase activity in adipocyte cell cultures, and this effect can be blocked by the preincubation with the CB1 selective antagonist rimonabant, thus confirming a specific cannabinoid mechanism of action .
Interestingly, the blockade of CB1 receptors, either in vivo or in adipocyte cell cultures, results in a significant increase of adiponectin production . Adiponectin is secreted exclusively by adipose tissue, with plasma levels negatively correlated with obesity . Moreover, adiponectin is the only adipocytokine with anti-inflammatory effects and with a protective role against atherosclerosis, in addition to its insulin sensitizer effect . The modulation of the endocannabinoid system using a chronic oral treatment with rimonabant simultaneously reduces body weight and stimulates adiponectin mRNA expression in adipose tissue of obese Zucker rats . In parallel, the hyperinsulinemia associated with this experimental model was reduced by rimonabant treatment . Moreover, adiponectin expression is up-regulated by the blockade of CB1 receptors only in CB1+/+, but not CB1-/- knockout, mice .
It has already been shown that the modulation of the endocannabinoid system regulates glucose uptake through the phosphatidylinositol-3-kinase pathway in skeletal muscle cells . Accordingly, the blockade of peripheral CB1 receptors could contribute to the improvement of glycemia observed in clinical trials with rimonabant . In this context, Liu et al. clearly demonstrated that a sub-acute treatment with rimonabant increases soleus muscle glucose uptake in leptin-deficient obese mice .
The presence of CB1 receptors in the mouse liver has been confirmed using multiple methodological approaches , indicating that the hepatocyte could be a peripheral molecular target of the endocannabinoid system. In fact, the activation of the CB1 receptor increases the expression of lipogenic genes in the liver, which is the main source of de novo fatty acid synthesis in the body .
Synthetic agonists of the CB1 receptor induce the expression of several key lipogenic enzymes in liver, an effect that is prevented by a pretreatment with CB1 receptor antagonists . Moreover, the basal rates of de novo fatty acid synthesis are markedly increased in CB1+/+ mice submitted to a high fat diet (HFD), compared with those of lean controls, but not in the CB1-/- knockout mice . The pretreatment of CB1+/+ mice on HFD with a CB1 receptor antagonist reduces the rate of fatty acid synthesis . In mice on HFD, the hepatic levels of the endocannabinoid anandamide were also greatly elevated. Finally, a marked deposition of lipid droplets was evident in wild-type, but not CB1-/- mice on HFD , suggesting the involvement of cannabinoid activation in liver steatosis.
The endocannabinoid system is present and has important physiological functions not only in the central nervous system but also in peripheral tissues. The activation of central CB1 receptors, particularly in hypothalamic nuclei and in the limbic system, is involved in the regulation of feeding behavior, and especially in the control of the intake of palatable food. It is important to mention that the activation of the endocannabinoid system, in addition to increasing appetite (total food intake), also influences the palatability and the preferential choice of tasty and sweet foods  (Figure 2). Thus, endocannabinoid antagonists could be utilized for the treatment of the type of obesity associated with specific eating disorders such as 'sweet and snack-eating' and compulsive eating episodes.
In the periphery, cannabinoid receptors are present in adipocytes, skeletal muscle, gastrointestinal tract and liver, modulating energy metabolism (Table 1).
In conclusion, the endocannabinoid system seems to play a key role in the development and maintenance of obesity (see previous reviews [5, 39, 40]). In obese patients, excessive food intake, especially of sweet and palatable food, could lead to the hyperactivity of the endocannabinoid system, resulting in several metabolic alterations typical of the metabolic syndrome (Figure 1). Thus, the pharmacological modulation of the endocannabinoid system turns out to be a unique target in the treatment of those that are overweight or obese .
- CB1 :
type 1 cannabinoid receptor
- CB2 :
type 2 cannabinoid receptor
Li HL, Lin H: An archaeological and historical account of cannabis in China. Econ Bot. 1974, 28 (4): 437-447.
Di Marzo V, Petrocellis LD: Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med. 2006, 57: 553-74. 10.1146/annurev.med.57.011205.135648.
Kogan NM, Mechoulam R: Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007, 9 (4): 413-30.
Abel EL: Cannabis: effects on hunger and thirst. Behav Biol. 1975, 15 (3): 255-81. 10.1016/S0091-6773(75)91684-3.
Cota D: Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord. 2003, 27 (3): 289-301. 10.1038/sj.ijo.0802250.
De Petrocellis L, Cascio MG, Di Marzo V: The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004, 141 (5): 765-74. 10.1038/sj.bjp.0705666.
Rodriguez de Fonseca F: The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005, 40 (1): 2-14.
Gaoni Y, Mechoulam R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964, 86: 1646-10.1021/ja01062a046.
Matsuda LA: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990, 346 (6284): 561-4. 10.1038/346561a0.
Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993, 365 (6441): 61-5. 10.1038/365061a0.
Howlett AC: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002, 54 (2): 161-202. 10.1124/pr.54.2.161.
Schlicker E, Kathmann M: Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001, 22 (11): 565-72. 10.1016/S0165-6147(00)01805-8.
Devane WA: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992, 258 (5090): 1946-9. 10.1126/science.1470919.
Felder CC: Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 1996, 393 (2-3): 231-5. 10.1016/0014-5793(96)00891-5.
Hanus L: Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem. 1993, 36 (20): 3032-4. 10.1021/jm00072a026.
Berry EM, Mechoulam R: Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther. 2002, 95 (2): 185-90. 10.1016/S0163-7258(02)00257-7.
Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005, 8 (5): 585-9. 10.1038/nn1457.
Kirkham TC: Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol. 2005, 16 (5-6): 297-313. 10.1097/00008877-200509000-00004.
Sharkey KA, Pittman QJ: Central and peripheral signaling mechanisms involved in endocannabinoid regulation of feeding: a perspective on the munchies. Sci STKE. 2005, 2005 (277): pe15-10.1126/stke.2772005pe15.
Pagotto U: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006, 27 (1): 73-100. 10.1210/er.2005-0009.
Pacher P, Batkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006, 58 (3): 389-462. 10.1124/pr.58.3.2.
Jamshidi N, Taylor DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol. 2001, 134 (6): 1151-4. 10.1038/sj.bjp.0704379.
Kirkham TC: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002, 136 (4): 550-7. 10.1038/sj.bjp.0704767.
Ravinet Trillou C: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004, 28 (4): 640-8. 10.1038/sj.ijo.0802583.
Cota D: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003, 112 (3): 423-31.
Ravinet Trillou C: Anti-obesity effect of SR14 a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 1716, 284 (2): R345-53.
Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 1988, 11 (1): 1-14. 10.1016/S0195-6663(88)80017-5.
Mattes RD: Cannabinoids and appetite stimulation. Pharmacol Biochem Behav. 1994, 49 (1): 187-95. 10.1016/0091-3057(94)90475-8.
Williams CM, Kirkham TC: Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1999, 143 (3): 315-7. 10.1007/s002130050953.
Koch JE: Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav. 2001, 68 (3): 539-43. 10.1016/S0091-3057(01)00467-1.
Vemuri VK, Janero DR, Makriyannis A: Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav. 2008, 93 (4-5): 671-86. 10.1016/j.physbeh.2007.11.012.
Bensaid M: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003, 63 (4): 908-14. 10.1124/mol.63.4.908.
Arita Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999, 257 (1): 79-83. 10.1006/bbrc.1999.0255.
Goldstein BJ, Scalia R: Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004, 89 (6): 2563-8. 10.1210/jc.2004-0518.
Esposito I: The cannabinoid CB1 receptor antagonist Rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating phosphatidylinositol-3-kinase activity. Mol Pharmacol. 2008
Scheen AJ: CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol. 2008, 20 (Suppl 1): 139-46. 10.1111/j.1365-2826.2008.01681.x.
Liu YL: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond). 2005, 29 (2): 183-7. 10.1038/sj.ijo.0802847.
Osei-Hyiaman D: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005, 115 (5): 1298-305.
Kirkham TC, Williams CM: Endogenous cannabinoids and appetite. Nutr Res Rev. 2001, 14 (1): 65-86. 10.1079/095442201108729141.
Cota D: Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity. J Endocrinol Invest. 2003, 26 (10): 1041-4.
Murro AL: The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant. Diabetol Metab Syndr. 2009, 1 (1): 18-10.1186/1758-5996-1-18.
Max Planck Institute of Psychiatry. News Release - Max Planck Society. 2002, 17:
The author declares that they have no competing interests.
ET conceived and wrote the manuscript. All authors read and approved the final manuscript.